Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a clinical-stage biopharmaceutical company pioneering conditionally activated immunotherapies for cancer treatment. This news hub provides investors and industry observers with essential updates on the company’s innovative pipeline, including its INDUKINE molecules WTX-330 and WTX-124 developed through the proprietary PREDATOR platform.
Access real-time announcements covering clinical trial progress, regulatory milestones, financial results, and strategic partnerships. Our curated collection ensures you stay informed about developments in immuno-oncology therapies designed to activate only within tumor microenvironments – a breakthrough approach aiming to improve safety profiles compared to traditional cytokine treatments.
Key updates include phase 1/2 trial data readouts, IND applications, collaboration agreements, and peer-reviewed research publications. All content is vetted for relevance to investment analysis and therapeutic advancement in solid tumors and immune-mediated diseases.
Bookmark this page for streamlined tracking of HOWL’s scientific and corporate developments. Combine our news feed with Stock Titan’s financial tools to monitor this innovator’s progress in redefining cancer immunotherapy.
Werewolf Therapeutics (Nasdaq: HOWL) reported significant advancements in their clinical pipeline, highlighting a collaboration with Merck to assess WTX-124 combined with KEYTRUDA. The company plans to file INDs for WTX-124 and WTX-330 in H1 2022. As of September 30, 2021, cash reserves totaled $170.4 million, a notable increase from $92.6 million at the end of 2020. However, net losses for Q3 2021 were $13.8 million, up from $6.1 million year-over-year. Overall, Werewolf's solid financial position supports its ongoing R&D efforts.
Werewolf Therapeutics (Nasdaq: HOWL), a pioneering biopharmaceutical company, has announced management will present at two key investor conferences this month. The Jefferies Global Healthcare Conference is scheduled for November 18th at 3:00 AM EST, followed by the Evercore ISI HealthCONx Conference on November 30th at 10:30 AM EST. The webcasts will be available on their investor relations webpage. The company aims to advance its innovative INDUKINE™ therapeutics, designed to activate the immune system against cancer, particularly through products WTX-124 and WTX-330.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced the appointment of Meeta Chatterjee, Ph.D., as a new board member. Dr. Chatterjee brings over 30 years of experience in pharmaceutical R&D and business development, previously serving at Legend Biotech Corporation and Merck Research Labs. She aims to enhance the company's strategy as it advances its lead product candidates, WTX-124 and WTX-330, targeting solid tumors. This strategic addition is anticipated to strengthen the board's capabilities during a pivotal time for the company's development.
Werewolf Therapeutics (Nasdaq: HOWL) announced the presentation of promising preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place from November 10-14, 2021. This data showcases the potential of their INDUKINE™ molecules, specifically WTX-124 and WTX-330, in enhancing anti-tumor immune responses. The results will be included in IND applications expected to be filed in the first half of 2022. The abstracts will be available on the SITC website starting November 9, 2021.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) will present at the Next-Gen Cytokine Therapeutics Summit on September 22, 2021. Chief Scientific Officer, Cynthia Seidel-Dugan, Ph.D., will discuss advancements in cytokine therapeutics at 4:20 PM EDT, followed by Chief Medical Officer, Randi Isaacs, M.D., on a panel discussing the future of cytokine therapies at 4:50 PM EDT. The company focuses on innovative therapeutics that leverage its proprietary PREDATOR™ platform to enhance cancer treatment through conditionally activated INDUKINE™ molecules.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL), based in Cambridge, Massachusetts, will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021. CEO Daniel J. Hicklin, Ph.D. will provide a company overview available on-demand starting September 13 at 7:00 am EDT, archived for 90 days. Werewolf specializes in developing conditionally activated therapeutics to enhance the immune system's response to cancer, leveraging its innovative PREDATOR™ platform and its lead candidates, WTX-124 and WTX-330, for solid tumors.
Werewolf Therapeutics has announced a clinical trial collaboration with Merck to evaluate WTX-124, a conditionally activated Interleukin-2 molecule, alongside KEYTRUDA® in treating solid tumors.
This trial will assess the safety and efficacy of WTX-124 both alone and in combination with KEYTRUDA. Werewolf plans to submit an IND application to the FDA in 2022, aiming to start Phase 1 trials if approved. WTX-124 is designed to enhance treatment while minimizing toxicity, potentially improving options for cancer patients.
Werewolf Therapeutics (Nasdaq: HOWL) announced its financial results for Q2 2021. The company raised approximately $109.2 million through its IPO in May, boosting cash reserves to $183.2 million. R&D expenses rose to $7.3 million from $3.8 million year-over-year, while general and administrative costs increased to $3.7 million from $1.3 million. The net loss for Q2 stood at $10.9 million compared to $2.3 million the previous year. Werewolf aims to file INDs for its INDUKINE™ products, WTX-124 and WTX-330, and was recently added to the Russell 2000 Index.
Werewolf Therapeutics will be added to the Russell 2000® Index on June 28, 2021, a significant milestone reflecting its progress in developing cancer therapeutics.
The company is advancing its lead programs, WTX-124 and WTX-330, into clinical trials. The Russell 2000® Index is a key benchmark representing the small-cap segment of the U.S. equity market, used by many institutional investors for index funds.
Approximately $10.6 trillion in assets benchmark against Russell's indexes, underlining the importance of this inclusion for Werewolf Therapeutics.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) has appointed Chulani Karunatilake, Ph.D., as the new Chief Technology Officer (CTO). With over 30 years of experience in Chemistry and Manufacturing Controls (CMC), Dr. Karunatilake will oversee manufacturing operations as the company advances its lead therapeutic programs, WTX-124 and WTX-330, which are designed to treat cancer. His prior experience includes roles at Maverick Therapeutics and Nektar Therapeutics, emphasizing drug development and regulatory management. This appointment aims to enhance Werewolf's capabilities in immuno-oncology.
FAQ
What is the current stock price of Werewolf Therapeutics (HOWL)?
What is the market cap of Werewolf Therapeutics (HOWL)?
